Obesity significantly impacts cardiovascular health, increasing risks such as left ventricular hypertrophy, atherosclerosis, ...

What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

DTC Telehealth Platforms - Arrangements involving telemedicine and direct-to-consumer (“DTC”) business services are expected to be a source ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular ...

This cohort study found that key sociodemographic, health care, and clinical factors are associated with receipt of semaglutide, a ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity ...

Significant associations for semaglutide initiation included being ... “These findings suggest that insurance plan type and structure may be a crucial intervention point for improving equity ...

Female sex, antidepressant use, and type of health insurance significantly influence semaglutide initiation ... suggest that insurance plan type and structure may be a crucial intervention ...

For GLP-1 receptors, it’s GLP-1. Ozempic, or semaglutide, is a GLP-1 agonist, meaning its molecules mimic the structure of GLP-1, binding to its receptor like a counterfeit key someone’s ...

PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a ...